Elamipretide clinical trials
Also written MTP-131, Bendavia and Bendavia 10mg.
How each study uses elamipretide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elamipretide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Sept 2025 · FORZINITY · NDA 215244 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 2 |
| 2019 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 1
Stealth BioTherapeutics Inc. (27) · Children's Hospital of Philadelphia (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antioxidants source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test elamipretide, phase 3 first.
- Aug 2027ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Phase 3 · Stealth BioTherapeutics Inc.
- May 2027Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth SyndromePhase 1 · Stealth BioTherapeutics Inc.
Studies
Open first, then newest update. How each study uses elamipretide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth SyndromeNot yet recruitingPhase 1Stealth BioTherapeutics Inc.NCT07927972Written as Elamipretide
- Clinical Trial in Patients With Barth Syndrome- 4TAZPowerRecruitingPhase 4Stealth BioTherapeutics Inc.NCT07531251Written as Elamipretide
- ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Active, not recruitingPhase 3Stealth BioTherapeutics Inc.NCT06373731Written as Elamipretide
- FRDA Investigator Initiated Study (IIS) With ElamipretideCompletedPhase 1/2Children's Hospital of PhiladelphiaNCT05168774Written as Elamipretide
- Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)CompletedPhase 3Stealth BioTherapeutics Inc.NCT05162768Written as Elamipretide
- ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GACompletedPhase 2Stealth BioTherapeutics Inc.NCT03891875Written as Subcutaneous elamipretide through the elamipretide delivery system
- A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth SyndromeCompletedPhase 2/3Stealth BioTherapeutics Inc.NCT03098797Written as Elamipretide
- A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label ExtensionTerminatedPhase 3Stealth BioTherapeutics Inc.NCT03323749Written as elamipretide
- Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)TerminatedPhase 2Stealth BioTherapeutics Inc.NCT02976038Written as elamipretide
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic NeuropathyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02693119Written as elamipretide (MTP-131) 1% topical ophthalmic solution
- An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular DegenerationCompletedPhase 1Stealth BioTherapeutics Inc.NCT02848313Written as Elamipretide
- Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal ArteryTerminatedPhase 1/2Stealth BioTherapeutics Inc.NCT01755858Written as Bendavia
- A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailureCompletedPhase 2Stealth BioTherapeutics Inc.NCT02914665Written as elamipretide
- Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER StudyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02805790Written as Elamipretide
- A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in ElderlyCompletedPhase 2Stealth BioTherapeutics Inc.NCT02245620Written as Elamipretide
- Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary EventsCompletedPhase 2Stealth BioTherapeutics Inc.NCT01572909Written as Bendavia (MTP-131)
- Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection FractionCompletedPhase 2Stealth BioTherapeutics Inc.NCT02788747Written as 4 mg elamipretide
- Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial MyopathyCompletedPhase 1/2Stealth BioTherapeutics Inc.NCT02367014Written as elamipretide (low dose)
- A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection FractionCompletedPhase 2Stealth BioTherapeutics Inc.NCT02814097Written as elamipretide
- A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal FunctionCompletedPhase 1Stealth BioTherapeutics Inc.NCT02436447Written as MTP-131
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call elamipretide · ClinicalTrials.gg INT004846
- MeSH (NLM) C506540elamipretideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 87GWG91S09ELAMIPRETIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27269822elamipretideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171874ElamipretideOne source FDA
- DrugBank DB11981One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506540 | elamipretide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 87GWG91S09 | ELAMIPRETIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27269822 | elamipretide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171874 | Elamipretide | One source FDA |
| DrugBank | DB11981 | — | One source Wikidata |
Also registered as elamipretide hydrochloride (UNII E40WZ3BK2D).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.